Topic: preclinical research
Genesis Drug Discovery & Development has bought up New England Discovery Partners as it looks to boost its synthetic and medicinal chemistry.
Cancer has always mirrored evolution, but now researchers are developing a new class of drug that blocks the mutations that lead to drug resistance.
The consortium intends to make new tools, models and processes broadly available, with a large focus on solutions geared toward cancer patients.
Researchers aim to employ onboard AI to improve the sophistication of prosthetic hands, and use deep learning to read the body’s nerve signals.
Atomwise launched two joint ventures—one testing drugs in tumor organoids, and one to develop epigenetic drugs for triple-negative breast cancer.
By engineering a working model of a beating heart, researchers at GSK and TARA Biosystems aim to predict how the body responds to potential drugs.
Andrew Parker gave his notice after receiving an offer from another biotech, leaving Zealand to search for a new CSO.
AbbVie and Principia are ending an autoimmunity-focused deal, with Principia regaining the rights to the immunoproteasome inhibitor program.
Charles River has added another string to its early-stage R&D bow by acquiring preclinical services firm Citoxlab for $510 million in cash.
eGenesis is bringing on William “Wes” Westlin, Ph.D., to help head up its xenotransplantation R&D as executive vice president.